BCL2 and tuberculosis: In the 15 active TB patients with second blood sampling, TLR2 (2.18 ± 1.94 versus 4.87 ± 4.06 fold change, p = 0.003, Figure 3h) and BCL2 (1 ± 1.19 versus 3.65 ± 4.05 fold change, p = 0.018, Figure 3i) gene expressions were both reduced after 6-month anti-TB therapy as compared with that before treatment.